Astellas Pharma (OTCMKTS:ALPMY) Stock Passes Above 50 Day Moving Average of $15.52

Astellas Pharma Inc. (OTCMKTS:ALPMYGet Rating) crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $15.52 and traded as high as $15.66. Astellas Pharma shares last traded at $15.66, with a volume of 83,346 shares traded.

Wall Street Analyst Weigh In

Separately, Citigroup assumed coverage on shares of Astellas Pharma in a research report on Tuesday, April 12th. They set a “buy” rating on the stock.

Astellas Pharma Stock Performance

The company has a market capitalization of $28.75 billion, a price-to-earnings ratio of 26.10, a P/E/G ratio of 0.74 and a beta of 0.55. The business’s 50-day simple moving average is $15.52 and its 200-day simple moving average is $15.97.

Astellas Pharma (OTCMKTS:ALPMYGet Rating) last released its earnings results on Wednesday, April 27th. The company reported ($0.04) earnings per share (EPS) for the quarter. Astellas Pharma had a net margin of 9.66% and a return on equity of 9.37%. The business had revenue of $2.62 billion for the quarter. On average, analysts forecast that Astellas Pharma Inc. will post 0.89 earnings per share for the current year.

Astellas Pharma Company Profile

(Get Rating)

Astellas Pharma Inc engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant.

Further Reading

Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with's FREE daily email newsletter.